The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Expansion In Market Value Is Forecasted For The Mammalian Cell Banking Market Between 2026 And 2030?

The mammalian cell banking market has seen rapid expansion in recent years. It is anticipated to increase from $3.14 billion in 2025 to $3.5 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 11.3%. The historic period’s growth can be linked to the development of monoclonal antibodies, an increase in vaccine manufacturing, the implementation of regulatory quality requirements, the expansion of academic research, and the commercialization of biologics.

The mammalian cell banking market is projected to undergo significant expansion in the next few years. It is expected to grow to $5.31 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.0%. This growth during the forecast period can be attributed to advancements in gene therapy, the expansion of personalized medicine, developments in biosimilars, the emergence of cell-based therapy pipelines, and the necessity for long-term cell traceability. Noteworthy trends in the forecast period include the standardization of cell line preservation, the increasing number of biopharmaceutical pipelines, the expansion of CGMP-compliant cell banks, a greater emphasis on genetic stability, and an rise in outsourcing to specialized facilities.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/mammalian-cell-banking-global-market-report

What Significant Factors Are Influencing The Mammalian Cell Banking Market Expansion?

An anticipated surge in the need for cell-based therapies is projected to drive the expansion of the mammalian cell banking market in the future. These therapies are advanced medical interventions that utilize living cells, frequently modified or engineered, to mend, substitute, or restore compromised tissues and organs, providing precise remedies for numerous ailments. The increasing occurrence of chronic and rare illnesses is fueling this demand, necessitating more efficacious and specific treatment avenues. Mammalian cell banking facilitates cell-based therapies by supplying a dependable, standardized reservoir of premium cells, guaranteeing uniformity, safety, and expandability in the creation and production of regenerative treatments. For example, reports from the American Society of Gene and Cell Therapy, a US-based non-profit medical and scientific organization, indicated in April 2024 that the quantity of therapies in all clinical pipeline phases has expanded since late 2023, with Phase I exhibiting the most significant rise of 11% compared to pre-fourth quarter 2022 levels. Consequently, the escalating demand for cell-based therapies is a primary impetus for the expansion of the mammalian cell banking market.

How Are Segments Identified Within The Mammalian Cell Banking Market Segment Framework?

The mammalian cell banking market covered in this report is segmented –

1) By Product Type: Master Cell Bank, Working Cell Bank

2) By Cell Type: Chinese Hamster Ovary Mammalian Cell Banking (CHO), Baby Hamster Kidney (BHK), Non-Secreting 0 (NS0), YB2/0 And P2/0, Human Embryonic Kidney 293 (HEK293) And Derivatives, Henrietta Lacks (HELA)

3) By Storage Type: Liquid Nitrogen, Controlled Rate Freezer, Flash Freezing

4) By Application: Drug Development, Vaccine Production, Gene Therapy, Monoclonal Antibody Production

5) By End User: Academic And Research Laboratories, Biopharmaceutical Companies, Contract Research Organizations (CROs)

Subsegments:

1) By Master Cell Bank: Recombinant Cell Lines, Hybridoma Cell Lines, Primary Cell Lines, Genetically Engineered Cell Lines, Viral Vector Producing Cell Lines

2) By Working Cell Bank: Current Good Manufacturing Practice (CGMP)-Compliant Cell Banks, Research-Grade Cell Banks, Clinical Trial Cell Banks, Commercial Production Cell Banks, Stability Testing Cell Banks

What Trends Are Affecting The Direction Of The Mammalian Cell Banking Market?

Leading companies in the mammalian cell banking market are prioritizing the creation of innovative solutions, such as advanced stable cell line systems, to improve cell line efficiency, ensure enduring genetic stability, and optimize biopharmaceutical manufacturing processes. Stable cell line systems consist of genetically engineered mammalian cells designed to reliably produce a desired protein or therapeutic compound over multiple generations, demonstrating strong genetic stability and reproducibility. For example, in August 2024, WuXi Biologics, a China-based biopharmaceutical company, introduced the WuXia293 Stable platform. This is an innovative HEK293-based stable cell line system specifically engineered for the development and production of biologic molecules that are challenging to express. Leveraging proprietary mammalian cell line development technology, this platform ensures consistent expression and uniform quality across prolonged cell passages. The WuXia293 Stable platform resolves difficulties associated with low yields and inferior quality observed with traditional CHO cell systems by delivering high protein titers, enhanced human-like glycosylation, and scalable production suitable for clinical and commercial manufacturing.

Who Are The Companies Competing Within The Mammalian Cell Banking Market?

Major companies operating in the mammalian cell banking market are Merck KGaA, Thermo Fisher Scientific Inc., Lonza Group AG, Eurofins Scientific SE, Charles River Laboratories International Inc., Catalent Inc., Sartorius Stedim Biotech S A, Samsung Biologics Co Ltd, CMIC Holdings Co Ltd, WuXi Biologics Inc., Evotec SE, AGC Biologics Inc., GenScript ProBio Co Ltd, Syngene International Limited, KBI Biopharma Inc., Rentschler Biopharma SE, Polpharma Biologics S A, Abzena plc, 53Biologics, Cellistic, GBI Biomanufacturing, ABL Inc, OmniaBio, uBriGene Biosciences

Get The Full Mammalian Cell Banking Market Report:

https://www.thebusinessresearchcompany.com/report/mammalian-cell-banking-global-market-report

Which Region Is The Largest In The Mammalian Cell Banking Market?

North America was the largest region in the mammalian cell banking market in 2025. The regions covered in the mammalian cell banking market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Mammalian Cell Banking Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/mammalian-cell-banking-global-market-report

Browse Through More Reports Similar to the Global Mammalian Cell Banking Market 2026, By The Business Research Company

Cell Cultures Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-cultures-global-market-report

Cell Harvesting Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-harvesting-global-market-report

Cell Based Assays Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-based-assays-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.